Intervention
epilepsy
EPILEPSY
Eligible and consenting trial participants were screened within 6 weeks before the start of the intervention phase and subsequently randomized to one of four arms to receive oral doses of either: pyrimethamine once a day for 14 days (200 mg on the first day followed by 100 mg onward), VPA (30 mg/kg per day) (divided into two equal doses) for 14 days, a combination of pyrimethamine and VPA dosed likewise, or no intervention. For the randomization process, an independent statistician delivered sealed opaque envelopes that included the study identifier with the allocated treatment based on random allocation performed in R. VPA and pyrimethamine were administered in dosages used in the chronic treatment of epilepsy (